LRP、TOPO-II在非小细胞肺癌中的协同表达及其临床意义

目的 探讨肺耐药蛋白(lung resistance protein，LRP)和DNA拓扑异构酶Ⅱ(topoisomerase-Ⅱ，TOPO-Ⅱ)在非小细胞肺癌(non-small cell lung cancer，NSCLC)中的协同表达及其临床意义。方法 用SP免疫组化方法检测62例术前均未进行化疗的NSCLC组织中LRP、TOPO-Ⅱ蛋白的表达情况。结果 在NSCLC中LRP、TOPO-Ⅱ蛋白表达的阳性率分别为75.8％(47/62例)；64.5％(40/62例)。LRP蛋白表达与分化程度相关。TOPO-Ⅱ蛋白表达与分化程度、有无淋巴结转移相关。LRP与TOPO-Ⅱ协同表达与生存率相关。结论 应用免疫组织化学方法检测NSCLC中LRP、TOPO-Ⅱ的表达对肿瘤的化疗药物选择和预后判断具有显的临床意义。

CO-EXPRESSION OF LRP AND TOPO-II IN NSCLC AND ITS CLINICAL SIGNFICANCE

? Objective To investigate the expression and the clinical relationship between LRP and TOPO-II in NSCLC. Method Immunohistochemical S-P method was used to examine the expression of LRPprotein andTOPO-II protein in 62 cases of NSCLC which had not been treated by chemotherapy before surgery. Result Of the 62 cases,the positive rates of LRP protein and TOPO-II proteinwere 75.8%(47/62) and 64.5%(40/62)respectively. The expression of LRP protein was correlated signficantly with the degree of the tumor cells. The expression of TOPO-II protein was correlated signficantly with the histological type and lymph node metastasis. The co-expression of LRP and TOPO-II was correlated with the survival rate. Conclusion The status of the expression of LRP and TOPO-II detected by immuohistochemistry is of clinical significance for chemotherapy and prognosis of NSCLC.